ARTICLE SUMMARY:
The $2.85 billion osteobiologics market is one of the fastest growing, albeit controversial, sectors of spine surgery. Cerapedics has the potential to usher in a new era by gaining the first FDA PMA for a bone graft enhancer for cervical spine fusion in a field lacking convincing clinical data.
Bone regeneration consists of complex processes, such as inflammation and formation of fibrous tissue and bony callus.
